Molidustat

Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia[1][2].

Product Specifications

CAS Number

[1154028-82-6]

Product Name Alternative

BAY 85-3934

UNSPSC

12352005

Hazard Statement

H302, H360, H372

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Molidustat.html

Purity

99.70

Solubility

DMSO : 5 mg/mL (ultrasonic)

Smiles

O=C1C(N2N=NC=C2)=CNN1C3=NC=NC(N4CCOCC4)=C3

Molecular Formula

C13H14N8O2

Molecular Weight

314.30

Precautions

H302, H360, H372

References & Citations

[1]Flamme I, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9 (11) :e111838.|[2]Yamamoto H, et al. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Am J Nephrol. 2021;52 (10-11) :884-893.